Seelos Therapeutics Selects SLS-002 (Intranasal Racemic Ketamine) For Inclusion In The U.S. Department Of Defense's Adaptive Platform Trial To Evaluate Potential Treatments For Post-traumatic Stress Disorder
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics has chosen its SLS-002 (Intranasal Racemic Ketamine) for inclusion in the U.S. Department of Defense's Adaptive Platform Trial, which aims to evaluate potential treatments for Post-traumatic Stress Disorder (PTSD).
November 27, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seelos Therapeutics' SLS-002 has been selected for a U.S. Department of Defense trial to assess treatments for PTSD, potentially boosting the company's profile and credibility in the biotech sector.
The inclusion of Seelos Therapeutics' SLS-002 in a Department of Defense trial is a positive development for the company, likely to increase investor confidence and potentially lead to an uptick in the stock price in the short term. This news highlights the company's progress in product development and its potential role in addressing PTSD, a significant medical need.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100